drugset / Trial / NCT01102426

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

NCT01102426

Phase 3 Completed 255 enrolled PharmaMar
RandomizedParallel-groupOpen-labelTreatment

Summary

Study of Plitidepsin in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Timeline

Start
2010-06
Primary completion
2017-11
Completion
2017-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 40 mg Oral
Subject Plitidepsin Peptide 5 mg/m2 Intravenous